| Literature DB >> 28741703 |
Manmeet Saluja1, Peter Gilling2.
Abstract
Intravesical bacillus Calmette-Guérin has been the standard of care for high-risk non-muscle-invasive bladder cancer for 40 years. It remains one of the most successful immunotherapies ever used. Bacillus Calmette-Guérin shows superior efficacy to alternative intravesical treatments, and has an established role in reducing both recurrence and progression in non-muscle-invasive bladder cancer. It remains relatively safe, and has acceptable tolerability of both local and systemic side-effects. The present review provides insights into the role of bacillus Calmette-Guérin compared with alternative treatments both in primary and refractory settings.Entities:
Keywords: adjuvant treatment; bacillus Calmette-Guérin; immunotherapy; non-muscle-invasive bladder cancer; urinary bladder neoplasms
Mesh:
Substances:
Year: 2017 PMID: 28741703 DOI: 10.1111/iju.13410
Source DB: PubMed Journal: Int J Urol ISSN: 0919-8172 Impact factor: 3.369